Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Prinses Máxima Centrum Voorpagina
Nederlands
English
Content zoeken bij Prinses Máxima Centrum
Voorpagina
Profielen
Onderzoeksgroepen
Uitrusting
Onderzoeksoutput
Prijzen
Activiteiten
Knipsels
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Paul B. Chapman
, Axel Hauschild
, Caroline Robert
, John B. Haanen
, Paolo Ascierto
, James Larkin
, Reinhard Dummer
, Claus Garbe
, Alessandro Testori
, Michele Maio
, David Hogg
, Paul Lorigan
, Celeste Lebbe
, Thomas Jouary
, Dirk Schadendorf
, Antoni Ribas
, Steven J. O'Day
, Jeffrey A. Sosman
, John M. Kirkwood
,
Alexander M.M. Eggermont
Brigitte Dreno, Keith Nolop, Jiang Li, Betty Nelson, Jeannie Hou, Richard J. Lee, Keith T. Flaherty, Grant A. McArthur
Toon overzicht 8 andere
Toon minder
Onderzoeksoutput
:
Bijdrage aan tijdschrift
›
Artikel
›
peer review
6895
Citaten (Scopus)
Overzicht
Vingerafdruk
Vingerafdruk
Duik in de onderzoeksthema's van 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation'. Samen vormen ze een unieke vingerafdruk.
Sorteer per
Gewicht
Alfabetische volgorde
Keyphrases
BRAF V600E mutation
100%
Improved Survival
100%
Melanoma
100%
Vemurafenib
100%
Dacarbazine
60%
Response Rate
40%
Progression-free Survival
30%
Interim Analysis
30%
Confidence Interval
20%
Overall Survival
20%
Previously Untreated
20%
Metastatic Melanoma
20%
Adverse Events
10%
Body Surface Area
10%
Randomized Clinical Trial
10%
Disease Progression
10%
Diarrhea
10%
Twice Daily
10%
Nausea
10%
Squamous Cell Carcinoma (SqCC)
10%
Arthralgia
10%
Dose Adjustment
10%
Risk of Death
10%
Toxic Effects
10%
Duration of Response
10%
Rash
10%
Alopecia
10%
Phase II Clinical Trial
10%
PLX4032
10%
Keratoacanthoma
10%
Relative Reduction
10%
Phase 1 Clinical Trial
10%
Safety Monitoring
10%
Data Monitoring
10%
Monitoring Boards
10%
Raf Kinase Inhibitor Protein
10%
Medicine and Dentistry
Vemurafenib
100%
Melanoma
100%
Dacarbazine
54%
Progression Free Survival
27%
Interim Analysis
27%
Overall Survival
18%
Metastatic Melanoma
18%
Clinical Trial
9%
Adverse Event
9%
Randomized Clinical Trial
9%
Squamous Cell Carcinoma
9%
Disease Exacerbation
9%
Diarrhea
9%
Nausea
9%
Body Surface
9%
Exanthem
9%
Photosensitivity
9%
Toxicity
9%
Alopecia Mucinosa
9%
Keratoacanthoma
9%
B Raf Kinase Inhibitor
9%
Arthralgia
9%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Vemurafenib
100%
Dacarbazine
54%
Progression Free Survival
27%
Overall Survival
18%
Metastatic Melanoma
18%
Clinical Trial
9%
Disease Exacerbation
9%
Diarrhea
9%
Adverse Event
9%
Arthralgia
9%
Squamous Cell Carcinoma
9%
Nausea
9%
Randomized Clinical Trial
9%
Toxicity
9%
Alopecia
9%
Rash
9%
Photosensitivity
9%
Keratoacanthoma
9%
B Raf Kinase Inhibitor
9%